GlassScriptPhysician profile
Johny Alencherry
NPI 1952387300
$27,309.76
in general payments reported to CMS, 2019-2025
39 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,909 · 2020: $3,738 · 2021: $17K · 2022: $3,133 · 2023: $424 · 2024: $233 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $29.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.95 |
| Education | $29.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21,926.80 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,211.06 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $974.24 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $434.54 | 2019-2021 | |
| Grifols USA, LLC | $358.08 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $305.61 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $262.62 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $207.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $193.30 | 2019-2020 | |
| Pfizer INC. | $173.73 | 2019-2025 | |
| Novo Nordisk INC | $146.27 | 2025 | Ozempic, Rybelsus, Wegovy |
| Genentech USA, INC. | $96.04 | 2019-2021 | |
| United Therapeutics Corporation | $90.54 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $83.06 | 2021 | |
| Lilly USA, LLC | $82.22 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johny Alencherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.